Heparin sodium Rx
Generic Name and Formulations:
Heparin sodium 1000, 5000, 10000units; per mL; IV or SC inj; preservative-free or preserved with benzyl alcohol.
Various generic manufacturers
Indications for Heparin sodium:
Adults and Children:
See full labeling. Individualize based on lab results and disease.
History of heparin-induced thrombocytopenia (HIT) or heparin-induced thrombocytopenia and thrombosis (HITT). Hypersensitivity to pork products. When blood coagulation testing is not feasible. Uncontrolled active bleeding state, except when due to disseminated intravascular coagulation.
IM use not recommended. Confirm choice of correct strength prior to administration. Monitor for any degree of thrombocytopenia; discontinue if platelet count falls <100000/mm3 or if recurrent thrombosis develops; evaluate for HIT and HITT; if needed, give alternative anticoagulant. Major bleeding or conditions with increased risk of hemorrhage (eg, bacterial endocarditis, severe hypertension, surgery, hemophilia, hereditary antithrombin III deficiency receiving concurrent antithrombin III therapy, ulcerative lesions, continuous GI tube drainage, menstruation, liver disease with impaired hemostasis). Monitor blood coagulation tests (discontinue if test is unduly prolonged or if hemorrhage occurs), platelets, hematocrit during therapy. Heparin resistance (monitor). History of allergy. Not interchangeable (unit-for-unit) with low molecular weight heparins. Women >60yrs of age. Elderly. Neonates/infants (gasping syndrome due to benzyl alcohol), pregnancy, nursing mothers: use preservative-free formulations.
Potentiated by anticoagulants (eg, dicumerol, warfarin), antiplatelets (eg, salicylic acid, dextran, phenylbutazone, ibuprofen, indomethacin, celecoxib, thienopyridines, dipyridamole, hydroxychloroquine, glycoprotein IIb/IIIa antagonists including abciximab, eptifibatide, tirofiban) and others; caution. Antagonized by digitalis, tetracyclines, nicotine, antihistamines, IV nitroglycerin. Potentiated by concurrent treatment with antithrombin III (human) in patients with hereditary antithrombin III deficiency; reduce heparin dose.
Hemorrhage, thrombocytopenia, HIT and HITT, inj site irritation, hypersensitivity reactions, increased aminotransferase levels.
Formerly known under the brand names Panheparin, Lipo-Hepin, Liquaemin.
Sign Up for Free e-newsletters
- Managing Chemo Brain in Pediatric Survivors of Childhood Cancer
- A Witness to Letting Go: Nursing Care at the End of Life
- CHEMO-SUPPORT: A Nursing Intervention to Relieve Chemotherapy Symptom Burden
- Intervention Improves Breast Cancer Survivors' Memory Contentment
- Excretion of Volatile Organic Compounds Higher in AYAs Using Vaping Products
- Various Aspects of Palliative Care Focus Associated With Different Outcomes In Cancer
- Cost vs Benefits: The Controversy Over Proton Beam Radiotherapy
- Patient Expectations at Odds With Actual Outcomes for Radiotherapy in Breast Cancer
- Patients Desire More Online Tools and Access
- Metformin Plus Ruxolitinib: A Potential Therapeutic Alternative for Myeloproliferative Neoplasms
- Medical Terms in Patient Education: Using the Confusing to Explain the Complicated
- Bedside Assessment Tool Improves Worst Pain in Patients With Cancer
- Androgen-Deprivation Therapy for Prostate Cancer May Cause Nocturia, Sleep Disturbance
- USPSTF Rates Ovarian Cancer Screening a D for Asymptomatic, Low-Risk Women
- Colorectal Cancer Screening Rate Increased by Digital Self-Ordering
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|